Monocyte Chemoattractant Protein-1 2518A/G Polymorphism

The pathogenesis of proliferative diabetic retinopathy (PDR) remains poorly understood. Recent studies have implicated that monocyte chemoattractant protein-1 (MCP-1) is associated with diabetic microvascular or macrovascular complications. However, the relationship between SNP polymorphism c.2518A/G in the MCP-1 gene with diabetic retinopathy remains controversial. In the present study, we evaluated the association of a single nucleotide polymorphism (SNP) in the MCP-1 gene with diabetic retinopathy (DR) and diabetic macular edema (DME) in Chinese population from Southern China with type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Retinopathy Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Endocrine System Diseases Eye Diseases Retinal Diseases Vascular Diseases

Age range

41 year–68 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Harbin Medical University

Harbin, Heilongjiang, 150001, China

About this study

The association between polymorphism of MCP-1 c.2518A/G and DR had been reported in Japan and Korea, but their opinion were inconsistent. However there is no report in China so far. This study was designed to clarify the relationship of polymorphism of MCP-1 c.2518A/G with type 2 diabetes with or without DR. The relationship between MCP-1 c.2518A/G and different stage of DR has also been studied.This article proved that the MCP-1 c.2518G/G genotype is a susceptibility gene for DR in Chinese type 2 diabetic patients, especially the High-risk PDR. There is no association with DME and c.2518G/G.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Type 2 diabetic retinopathy
age at diagnosis ≥30 years and a known duration of diabetes of ≥5 years.

Exclusion criteria

eyeball atrophy
epimacular membrane
age-related macular degeneration (ARMD)
intravitreal injection medicine
vitreous hemorrhage

Treatment and study plan

Primary outcomes

Genetic association

Time frame: 1 year

age at diagnosis of diabetes ≥30 years and a known duration of diabetes of ≥5 years.

Sponsors and collaborators

Lead sponsor

Harbin Medical University

Other

Registry information

Official study title

Association of Monocyte Chemoattractant Protein-1 (MCP-1)2518A/G Polymorphism With Proliferative Diabetic Retinopathy in Northern Chinese Type 2 Diabetes

Acronym: MCP-1

Important dates

Study start: 2011
Primary completion: 2013
Study completion: 2013
First posted: Mar 4, 2014
Registry last updated: Mar 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed